Nephrotic syndrome induced by pamidronate

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1196-1200

  Ten Dam, M A G J ^a   Hilbrands, L B ^b   Wetzels, J F M ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Nephrotic syndrome; Renal side effects

Indexed keywords

ATORVASTATIN; CREATININE; FUROSEMIDE; LISINOPRIL; PAMIDRONIC ACID; PREDNISONE; SERUM ALBUMIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE METASTASIS; CASE REPORT; COLLAPSING FOCAL GLOMERULOSCLEROSIS; CONVALESCENCE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; LABORATORY TEST; MALE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; RISK FACTOR; SODIUM RESTRICTION;

ADENOCARCINOMA; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; KIDNEY TRANSPLANTATION; MALE; NEPHROTIC SYNDROME; PROSTATIC NEOPLASMS;

EID: 84655176745     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9628-7     Document Type: Article

References (33)

1. JR Berenson A Lichtenstein L Porter 1996 Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group N Engl J Med 334 8 488 493
2. GN Hortobagyi RL Theriault A Lipton 1998 Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 6 2038 2044
3. TJ Polascik RW Given C Metzger 2005 Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases Urology 66 5 1054 1059
4. MD Michaelson MR Smith 2005 Bisphosphonates for treatment and prevention of bone metastases J Clin Oncol 23 32 8219 8224
5. T Tanvetyanon PJ Stiff 2006 Management of the adverse effects associated with intravenous bisphosphonates Ann Oncol 17 6 897 907
6. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
7. VD D'Agati AB Fogo JA Bruijn JC Jennette 2004 Pathologic classification of focal segmental glomerulosclerosis: a working proposal Am J Kidney Dis 43 2 368 382
8. JA Schwimmer GS Markowitz A Valeri GB Appel 2003 Collapsing glomerulopathy Semin Nephrol 23 2 209 218
9. JK Deegens EJ Steenbergen GF Borm JF Wetzels 2008 Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population-epidemiology and outcome Nephrol Dial Transplant 23 1 186 192
10. GS Markowitz GB Appel PL Fine 2001 Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate J Am Soc Nephrol 12 6 1164 1172
11. R Desikan Y Veksler S Raza 2002 Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma Br J Haematol 119 2 496 499
12. M Kunin J Kopolovic A Avigdor EJ Holtzman 2004 Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient Nephrol Dial Transplant 19 3 723 726
13. YM Barri NC Munshi S Sukumalchantra 2004 Podocyte injury associated glomerulopathies induced by pamidronate Kidney Int 65 2 634 641
14. M Shreedhara AZ Fenves D Benavides MJ Stone 2007 Reversibility of pamidronate-associated glomerulosclerosis Proc (Bayl Univ Med Cent) 20 3 249 253
15. V Jotterand S Moll P-Y Martin P Saudan 2009 Bisphosphonates-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review Nephrologie & Therapeutique 5 134
16. M Nagahama DA Sica 2009 Pamidronate-induced kidney injury in a patient with metastatic breast cancer Am J Med Sci 338 3 225 228
17. GS Markowitz PL Fine VD D'Agati 2002 Nephrotic syndrome after treatment with pamidronate Am J Kidney Dis 39 5 1118 1122
18. N Gokden M Zangari F Elici B Barlogie J Kumar 2007 Potential effect of zoledronate therapy in heavy proteinuria Clin Nephrol 67 4 263 265
19. J Pascual J Torrealba J Myers 2007 Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate Osteoporos Int 18 10 1435 1438
20. M Bodmer P Amico MJ Mihatsch 2007 Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient Nephrol Dial Transplant 22 8 2366 2370
21. E Hiroi-Furuya T Kameda K Hiura 1999 Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts Calcif Tissue Int 64 3 219 223
22. M Sauter B Julg S Porubsky 2006 Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47 6 1075 1080
23. GS Markowitz PL Fine JI Stack 2003 Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 1 281 289
24. S Smetana A Michlin E Rosenman A Biro M Boaz Z Katzir 2004 Pamidronate-induced nephrotoxic tubular necrosis-a case report Clin Nephrol 61 1 63 67
25. M Buysschaert JP Cosyns L Barreto M Jadoul 2003 Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism Nephrol Dial Transplant 18 4 826 829
26. DK Janssen van B Neyns NP Van der D Verbeelen 2001 Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases Nephron 89 4 467 468
27. LS Rosen D Gordon M Kaminski 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 8 1735 1744
28. RS McDermott DD Kloth H Wang GR Hudes CJ Langer 2006 Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model J Support Oncol 4 10 524 529
29. IJ Diel R Weide H Köppler 2009 Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical record review Support Care Cancer 17 719 725
30. R Bergner IJ Diel D Henrich M Hoffman M Uppenkamp 2006 Differences in nephrotoxicity of intravenous bisphophonates for the treatment of malignancy related bone disease Onkologie 29 534 540
31. JJ Body T Pfister F Bauss 2005 Preclinical perspectives on bisphosphonate renal safety Oncologist 19 3 7
32. American Society of Clinical Oncology 2007 Clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 17 2464 2472
33. PD Miller C Roux S Boonen IP Barton LE Dunlap DE Burgio 2005 Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials J Bone Miner Res 20 12 2105 2115